Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

18.24 -0.64 (-3.39%)

Streaming Delayed Price Updated: 10:53 AM EST, Feb 23, 2026 Add to My Watchlist

Price and Volume

Volume	269,297
Open	18.72
Bid (Size)	18.22 (300)
Ask (Size)	18.26 (200)
Prev. Close	18.88
Today's Range	18.24 - 19.01
52wk Range	10.41 - 109.55
Shares Outstanding	93,148,652
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy ↗

February 20, 2026

While Sarepta’s gene therapy for the treatment of DMD called Elevidys was approved by the FDA in 2023, Regenxbio is developing its treatment.

Via Stocktwits

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

February 11, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Performance

YTD	-14.4%	-14.4%
1 Month	-13.7%	-13.7%
3 Month	-3.5%	-3.5%
6 Month	+1.0%	+1.0%
1 Year	-82.7%	-82.7%

More News

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

February 04, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Did SRPT Stock Rise 6% In Pre-Market Today? ↗

January 26, 2026

Via Stocktwits

SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns ↗

January 12, 2026

Via Stocktwits

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

January 26, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Which stocks are moving after the closing bell on Friday? ↗

January 23, 2026

Via Chartmill

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

January 23, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

2 Beaten-Down Stocks That Could Sink Even More in 2026 ↗

January 21, 2026

Via The Motley Fool

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

January 12, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease

January 07, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 31, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Why Is SRPT Stock Falling Today? ↗

December 11, 2025

Via Stocktwits

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

December 11, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears

December 09, 2025

Via MarketMinute

Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results

December 03, 2025

Via MarketMinute

How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗

December 02, 2025

Via Investor's Business Daily

Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys ↗

November 25, 2025

Via Stocktwits

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

November 25, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

November 24, 2025

From Sarepta Therapeutics, Inc.

Via Business Wire

Tech Edges Up Ahead Of Nvidia's Earnings, Bitcoin Sinks Below $90,000: What's Moving Markets Wednesday? ↗

November 19, 2025

Via Benzinga

Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy ↗

November 17, 2025

Via Stocktwits

2 Beaten-Down Stocks to Avoid Right Now ↗

November 15, 2025

Via The Motley Fool

Sarepta Shares Jump After FDA Approves Updated Elevidys Label ↗

November 14, 2025

Via Benzinga

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. - Common Stock publicly traded?

Yes, Sarepta Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Sarepta Therapeutics, Inc. - Common Stock trade on?

Sarepta Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Sarepta Therapeutics, Inc. - Common Stock?

The ticker symbol for Sarepta Therapeutics, Inc. - Common Stock is SRPT on the Nasdaq Stock Market

What is the current price of Sarepta Therapeutics, Inc. - Common Stock?

The current price of Sarepta Therapeutics, Inc. - Common Stock is 18.24

When was Sarepta Therapeutics, Inc. - Common Stock last traded?

The last trade of Sarepta Therapeutics, Inc. - Common Stock was at 02/23/26 10:53 AM ET

What is the market capitalization of Sarepta Therapeutics, Inc. - Common Stock?

The market capitalization of Sarepta Therapeutics, Inc. - Common Stock is 1.70B

How many shares of Sarepta Therapeutics, Inc. - Common Stock are outstanding?

Sarepta Therapeutics, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.